Subscribe:
News
The 2013 Canadian Diabetes Association Clinical Practice Guidelines are coming!
Every 5 years, since 1998, the Clinical & Scientific Section of the Canadian Diabetes Association has published comprehensive, evidence-based recommendations for healthcare professionals to consider in the prevention and management of diabetes in Canada. Dr. Alice Cheng, Chair of the 2013 Clinical Practice Guidelines shares some of the important changes that have taken place in the development of the 2013 guidelines.
Spotlight on Research: Dr. Jean Buteau
Dr. Buteau PhD thesis investigated the action of Glucagon-Like Peptide-1 (GLP-1). As such, GLP-1 and its analogs have been subject to intensive investigation as anti-diabetes medications. Dr. Buteau was one of the first investigators to demonstrate the effects of GLP-1 on pancreatic beta-cell proliferation and survival, revealing a previously unrecognized mode of action of this new class of anti-diabetes medications.
You Asked for It …You Got It!
Maureen Clement, Chair of the Clinical & Scientific Section (C&SS), tells you about C&SS Connect—a commitment of the C&SS Executive Committee to provide quarterly updates about the people and projects that make up the C&SS.
Statins may raise blood glucose: Should we be concerned?
On February 28, 2012, the US Food and Drug Administration (FDA) approved new safety label changes for the statin class of cholesterol-lowering drugs.1 These changes included a statement regarding the effect of statins on blood glucose. The FDA stated that “increases in blood sugar levels have been reported with statin use.” However, they also indicated that “the cardiovascular benefits of statins outweigh these small increased risks.”
 |
Support the Canadian Diabetes Association! |